Views & Analysis

Views & Analysis
What should industry consider next time

VPAS 2024: What should industry consider next time?

The UK pharmaceutical industry is just getting to grips with working under two new approaches to regulating branded medicines spend; the 2019 Voluntary Scheme for Branded Medicines Pricing

Digital
China in the fast lane

China in the fast lane

Brett Gardiner and Boon Yap from Research Partnership discuss access opportunities for novel therapies in the world’s hottest emerging market